Lijin Biomedical Technology Shanghai

Ligen Biosciences is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of next-generation cancer immunotherapies. The company utilizes its proprietary xLink platform to engineer immune-modulating antibodies with optimized therapeutic windows, focusing on targets such as 4-1BB, PD-1, and CD40. Its lead candidate, LVGN6051 (exlinkibart), is a humanized 4-1BB agonist designed to provide potent anti-tumor activity while minimizing the liver toxicity typically associated with this class of drugs. Ligen's pipeline includes several monoclonal and bispecific antibodies being evaluated as monotherapies and in combination regimens for various refractory solid tumors.